Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iohexol
Drug ID BADD_D01180
Description Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Indications and Usage Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Marketing Status approved
ATC Code V08AB02
DrugBank ID DB01362
KEGG ID D01817
MeSH ID D007472
PubChem ID 3730
TTD Drug ID D02BLO
NDC Product Code 43228-100; 0407-1413; 71806-141; 0407-1414; 0407-1416; 0407-1415; 0407-1401; 0407-1411; 0407-1412; 65072-0801; 54702-501
UNII 4419T9MX03
Synonyms Iohexol | Iohexol 350 | Nycodenz | Compound 545 | Exypaque | Omnipaque
Chemical Information
Molecular Formula C19H26I3N3O9
CAS Registry Number 66108-95-0
SMILES CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thrombosis24.01.01.006--Not Available
Thyrotoxic crisis05.02.02.004; 19.07.03.006; 14.11.01.016; 06.09.04.0040.010670%Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.0020.021340%Not Available
Tongue oedema10.01.05.008; 23.04.01.009; 07.14.02.0070.021340%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.014227%
Tremor17.01.06.0020.304453%
Trismus17.01.03.004; 15.05.04.0040.010670%
Type I hypersensitivity10.01.03.0060.007113%Not Available
Unresponsive to stimuli17.02.05.0310.117371%Not Available
Urethral disorder20.07.01.002--Not Available
Urinary incontinence17.05.01.008; 20.02.02.0100.081804%
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.0014.764547%
Vein discolouration24.03.02.0040.007113%Not Available
Venous thrombosis24.01.01.0080.007113%Not Available
Ventricular fibrillation02.03.04.0080.071134%
Ventricular tachycardia02.03.04.0100.035567%
Vertigo04.04.01.003; 17.02.12.002--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.10.013--Not Available
VIth nerve paralysis06.05.02.009; 17.04.02.002--Not Available
Vomiting07.01.07.0031.109688%
Vomiting projectile07.01.07.0120.046948%Not Available
Wheezing22.03.01.0090.194907%
Withdrawal syndrome19.07.06.023; 08.06.02.012--Not Available
Yawning22.12.03.0370.014227%Not Available
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.0080.015649%Not Available
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.007113%Not Available
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.0060.010670%
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene